![](/img/cover-not-exists.png)
2098 ORAL BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC)
T. Pienkowski, M. Pegram, J. Forbes, V. Valero, W. Eiermann, G. Von Minckwitz, M. Martin, J. CrownVolume:
5
Year:
2007
Language:
english
DOI:
10.1016/s1359-6349(07)70860-1
File:
PDF, 77 KB
english, 2007